Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (April 2026)
31 slides from Prescient Therapeutics's investor presentation, Apr 30, 2026
Slide 1: Investor Briefing April 2026
For personal use only Investor Briefing April 2026 ASX: PTX ptxtherapeutics.com
Slide 2: Disclaimer and Safe Harbour
Disclaimer and Safe Harbour For personal use only Certain statements made in this document are forward-looking statements within the Certain statements contained in this document, including, without limitation, meaning of the safe harbor provisions of the United States Private Securities Litigation
Slide 3: Company snapshot: Key Metrics
Company Key Metrics snapshot ASX Ticker PTX For personal use only Total Issued Capital 1,051 M shares Share Price1 A$0.059 Market Capitalisation1 A$58 M Cash Position2 A$11.9M Top 20 Own 21% 1. As at 10 March 2026 2. As at 31 March 2026 (4C)
Slide 4: Our Focus
Our Focus For personal use only Bringing new hope Pioneering a therapeutic Creating value to people with cancer approach with the for both investors potential to address and patients ~1 in 5 cancers
Slide 5: Our unique value proposition
Our unique value proposition First-in-class approach to a proven pathway For personal use only Pioneering First disease target (CTCL) technology delivering strong data • PTX-100 is the most advanced • One of the most advanced cancer therapies on the ASX selective GGTase-1 inhibitor • Efficacy signal
Slide 6: Background
For personal use only Background
Slide 7: What causes cancerous mutations?
What causes cancerous mutations? For personal use only Normal cell growth Normal cell Cell division Healthy tissue Abnormal cell growth Normal cell Genetic changes Cancerous cell division Malignant tumour Mediated by the RAS family Source: https://www.cancerfoundation.org.au/what-is-cancer-.html
Slide 8: PTX-100 technology highlights
PTX-100 technology highlights For personal use only PTX-100 is licensed Inhibits the enzyme GGTase-1, crucial to the RAS pathway from Yale University • RAS proteins are among the highest priority targets in cancer drug development • Mutations in RAS proteins drive the development First-in-class drug
Slide 9: How PTX-100 works
Placeholder: How PTX-100 works RAS proteins can drive overgrowth of cells through PTX-100 blocks GGTase-1, For personal use only many signaling pathways, regulated by GGTase-1 broadly inhibiting RAS proteins signaling Cell Cell me me mb mb ra ra ne ne RAS GGTase-1 RAS Family Family GGTase-1 ON ON PT
Slide 10: First-in class advantages
First-in class advantages For personal use only First and only GGTase-1 inhibitor to reach clinical development1 This position potentially allows Prescient to: Eligibility for favorable regulatory designations that may support expedited development timelines2 Move through development without competi
Slide 11: A differentiated mode of action
A differentiated mode of action For personal use only Lymphir® Adcetris® Poteligo® Campath® *IPH4120 *BI-1808 Receptor DT MMAE TYR Kinase IL-2 Cell Induced Death Cytotoxicity CD25 CD30 CCR-4 CD52 KIR3DL2 TNFR2 RAS Family Protein GRB2 SOS GTP PTX-100 approach PTX-100 Cell death; reduced migration, su
Slide 12: PTX-100 for CTCL
For personal use only PTX-100 for CTCL
Slide 13: Strategy and data
Strategy and data For personal use only First indication Selection Outcomes chosen for: made: CTCL so far: • Strong RAS involvement • RAS family involvement • Phase 1b results: 100% clinical benefit2 (including • High unmet need • Orphan disease stable disease) and no drug- • Strong chance of • Adva
Slide 14: CTCL patients face a high unmet medical need
CTCL patients face a high unmet medical need For personal use only Poor outcomes in advanced stages Significant impact on quality of life 94% 84% 78% • Pruritus (itching) • Secondary infections 47% 47% 5Y-OS (%) 40% 37% • Appearance impacted 18% 18% by skin involvement • Sleep disturbance and fatigu
Slide 15: CTCL has limited effective treatment options
CTCL has limited effective treatment options For personal use only • A rare type of cancer of white blood cells (T cells), normally involved in immune function • These cancerous T cells are present in the skin, where they divide uncontrollably, attacking the skin and eventually impacting nodes and v
Slide 16: CTCL Clinical Data
For personal use only CTCL Clinical Data
Slide 17: Phase 1b with sub-analysis of CTCL patient cohort
Phase 1b with sub-analysis of CTCL patient cohort Response rates, safety and duration are key drivers For personal use only PTX-100 PTX-100 Benchmark1 Lymphir2,3 (Phase 1B)4 (CTCL only)5 Response Rate 30% 36% 45% 43% Clinical Benefit Rate 45% NA 64% 100% 9-13 months CTCL Duration of Response 6.5 mon
Slide 18: PTX-100: Favourable safety profile compared to peers
PTX-100: Favourable safety profile compared to peers Recommended CTCL drugs have challenging safety profiles, with adverse events occurring in up to 70% of patients For personal use only Adverse events associated with current marketed drugs and PTX-100 PTX-100 has a favourable safety profile • Data
Slide 19: Progressing PTX-100 Through Phase
Progressing PTX-100 Through Phase 2 For personal use only r/r CTCL 500mg/m2 x 20 pts 2 lines of prior systemic Dose Phase 2b Phase 2a treatment Optimisation Efficacy Dose Optimisation Committee X 75 pts Enrolment 1000mg/m2 x 20 pts X 40 patients (pts) Randomization Dose confirmation Multicenter clin
Slide 20: PTX-100 (CTCL): Status
PTX-100 (CTCL): Status For personal use only Clinical Trial Basic Preclinical Phase I Phase II Phase III MA On Market Research Studies Safety Dose finding Confirmatory PTX-100 Studies and efficacy efficacy and studies safety studies (CTCL) 2023 2024 Orphan Investigational Drug New Drug Engagement De
Slide 21: PTX-100 (CTCL): Proposed approach
Potential for a Phase 2b registrational study, subject to FDA agreement on endpoints. PTX-100 (CTCL): Proposed approach For personal use only Clinical Trial P o t e n t i a l d e v e l o p m e n t efficiencies Basic Preclinical Phase I Phase II MA On Market Research Studies Safety Dose finding PTX-1
Slide 22: Total addressable market
Total addressable market High unmet need = large market opportunity For personal use only US market for CTCL • 30001 new CTCL cases per year in the US • Estimated US CTCL market size of approximately ~US$1.2bn / year by 20342 1. JAMA Oncology.2022 Sep1;8(11):1690–1692.doi:10.1001/jamaoncol.2022.3236
Slide 23: New entrants for CTCL can grow the market
New entrants for CTCL can grow the market For personal use only CTCL US Market 2020 to 20251 (US$M) $800 $700 $600 Early results position PTX-100 $500 well against current therapies $400 $300 • Enable market share growth $200 • Unique MOA supports $100 combination opportunities $0 2020 2021 2022 202
Slide 24: CTCL program Summary
CTCL program Summary For personal use only PTX-100 PTX-100 (Phase 1B)1 (CTCL only)2 • Phase 1B results exceed benchmarks and existing drugs Response Rate 45% 43% • Allows for new indications with PTX-100 to go straight into Clinical Benefit Rate 64% 100% Phase 1b/2a Duration of Response 10.7 months
Slide 25: PTX-100's Wider Platform Opportunity
For personal use only PTX-100’s Wider Platform Opportunity
Slide 26: Major expansion opportunity with PTX-100
Major expansion opportunity with PTX-100 RAS pathway alterations are reported in ~ 22% of cancers For personal use only • Underlying biology targeted is relevant to 1 in 5 cancers • Potential to progress future indications into Phase 1b or 2a1 Clinical Trial Basic Preclinical Phase I Phase II Phase
Slide 27: Expansion strategy
Expansion strategy For personal use only Stage 1: CTCL-centric Stage 2: Expansion Demonstrate efficacy & safety • Bring new indications onto platform ⁻ Potentially partner the asset • Progressively address further cancers FDA support (ODD, FTD) • Strategic commercial pathways • Complete phase 2b reg
Slide 28: Board and management
Board and management Experienced team of drug developers and deal makers with track record in blood cancers For personal use only Management Team Experienced gained in global companies James McDonnell Dr Rebecca Tunstall Dr Marissa Lim Upaly Bahadure Dr Luis Malaver-Ortega CEO COO Chief Medical Offi
Slide 29: Our unique value proposition
Our unique value proposition First-in-class approach to a proven pathway For personal use only Pioneering First disease target (CTCL) technology delivering strong data • PTX-100 is the most advanced • One of the most advanced cancer therapies on the ASX selective GGTase-1 inhibitor • Efficacy signal
Slide 30: Thank you
For personal use only Thank you April 2026 ASX: PTX ptxtherapeutics.com
Slide 31: Appendix
For personal use only Appendix
Prescient Therapeutics — Investor Presentation (April 2026) on 6ix